Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Mar;20(3):779-787.
doi: 10.1111/ajt.15622. Epub 2019 Oct 23.

Sirolimus vs mycophenolate mofetil (MMF) in primary combined pancreas and kidney transplantation. Results of a long-term prospective randomized study

Peter Girman  1 , Květoslav Lipár  2 , Matěj Kočík  2 , Luděk Voska  3 , Radomíra Kožnarová  1 , Tomáš Marada  2 , Věra Lánská  4 , František Saudek  1
Affiliations
Free article
Randomized Controlled Trial

Sirolimus vs mycophenolate mofetil (MMF) in primary combined pancreas and kidney transplantation. Results of a long-term prospective randomized study

Peter Girman et al. Am J Transplant. 2020 Mar.
Free article

Abstract

The study was intended to compare pancreas graft survival rates in two groups of pancreas and kidney transplant recipients prospectively randomized to treatment either with sirolimus or MMF. From 2002 to 2013, 238 type 1 diabetic recipients with end-stage kidney disease were randomized 1:1 to sirolimus or MMF treatment. Noncensored pancreas survival at 5 years was 76.4 and 71.6% for sirolimus and MMF groups, respectively (P > .05). Death-censored pancreas survival was better in the sirolimus group (P = .037). After removal of early graft losses pancreas survival did not differ between groups (MMF 83.1% vs sirolimus 91.6%, P = .11). Nonsignificantly more grafts were lost due to rejection in the MMF group (10 vs 5; P = .19). Cumulative patient 5-year survival was 96% in the MMF group and 91% in the sirolimus group (P > .05). Five-year cumulative noncensored kidney graft survival rates did not statistically differ (85.6% in the sirolimus group and 88.8% in MMF group). Recipients treated with MMF had significantly more episodes of gastrointestinal bleeding (7 vs 0, P = .007). More recipients in the sirolimus group required corrective surgery due to incisional hernias (21 vs 12, P = .019). ClinicalTrials No.: NCT03582878.

Keywords: clinical research/practice; diabetes: type 1; immunosuppressant - mechanistic target of rapamycin: sirolimus; pancreas/simultaneous pancreas-kidney transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011;8(1):6-16.
    1. Saudek F, Malaise J, Boucek P, Adamec M, Euro S. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant. 2005;20(Suppl 2):ii3-10, ii62.
    1. Wakil K, Sugawara Y, Kokudo N, Kadowaki T. Causes of graft failure in simultaneous pancreas-kidney transplantation by various time periods. In Clinical Transplants. Los Angeles, CA: Terasaki Research Institute; 2013:23-30.
    1. Berney T, Andres A, Toso C, Majno C, Squifflet JP. mTOR inhibition and clinical transplantation: pancreas and islet. Transplantation. 2018;102(2S Suppl 1):S30-S31.
    1. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet. 2000;356(9225):194-202.

Publication types

Associated data